EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece
| Autor: | Loupas, MA, Lioliou, K, Gourzoulidis, G, Vostitsanou, Z, Giannakopoulou, A, Kourlaba, G |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S85-S85 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect